Gregg Berdy is an Ophthalmology physician affiliated with Ophthalmology Associates. OpenAlex indexes 48 publications with 1,303 citations (h-index 21); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12990 Manchester Rd
Suite 200
Saint Louis, MO 631311860
Telephone
314-966-5000Registry record last updated 30 Mar 2015.
Clinical trials
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Sponsor: Kala Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
29 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bausch & Lomb Americas Inc.Program year202536 payments$24,748openpaymentsdata.cms.gov ↗
- Tarsus Pharmaceuticals, Inc.Program year202525 payments$24,250openpaymentsdata.cms.gov ↗
- Oyster Point Pharma, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
56.5%Corticosteroids, plain13.3%Lotemax Sm82%Lotemax13%Loteprednol Etabonate5%Part D<11 patientsProstaglandin analogues8.3%Vyzulta100%Part D≥57 patients+ 10 more classes in this area
Anti-infectives
23.8%Macrolide Antimicrobial9.8%Azithromycin79%Azasite21%Part D≥40 patientsFluoroquinolone Antibacterial3.8%Moxifloxacin100%Part D≥48 patients+ 4 more classes in this area
Cardiovascular
9.4%Beta blocker5.9%Timolol Maleate100%Part D≥40 patientsOther lipid modifying agents2.2%Vascepa65%Icosapent Ethyl35%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”